Key Drivers
- Liquidity Strength
- Heavy Cash Burn
- Deep Losses
AIAI Summary
RLAY has moved from a pure cash-burn biotech to a credible late-stage catalyst story centered on zovegalisib and its Breakthrough Therapy designation, but the stock is still a binary bet because upside now depends on Phase 3/regulatory validation while burn, dilution pressure, and weak technicals leave little margin for error.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Heavy Cash Burn
- •Deep Losses
RLAY has a fortress-like balance sheet with ample cash and minimal debt, but severe losses, negative cash flow, and an extremely high sales multiple make the stock financially risky despite strong liquidity.
Price Behavior
Key Price Behavior Insights:
- •Broken support
- •Lower highs
- •Weak momentum
Over the last month, RLAY has broken key support and remains in a short-term downtrend unless it reclaims $13.00–$13.20.
Fell about 27% from $16.80 to $12.20 as recent support at $12.50–$12.70 failed
Sentiment & News
Key News Insights:
- •Phase 3 Path
- •Breakthrough Designation
- •Wider Loss
Relay Therapeutics reported encouraging zovegalisib combination data, FDA Breakthrough Therapy designation, and a wider-than-expected Q1 loss, highlighting strong pipeline momentum ahead of planned Phase 3 development.
Overall, this is modestly positive for Relay Therapeutics, as clinical and regulatory progress should support sentiment even as earnings remain under pressure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings